Comparative Pharmacology
Head-to-head clinical analysis: AZITHROMYCIN versus ERY TAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZITHROMYCIN versus ERY TAB.
AZITHROMYCIN vs ERY-TAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting mRNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.
250-500 mg orally every 6 hours or 333-666 mg every 8 hours. Maximum 4 g/day.
None Documented
None Documented
Clinical Note
moderateAzithromycin + Norfloxacin
"Azithromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateAzithromycin + Ibandronate
"Azithromycin may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateAzithromycin + Indapamide
"Azithromycin may increase the QTc-prolonging activities of Indapamide."
Clinical Note
moderateAzithromycin + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Azithromycin resulting in a loss in efficacy."
Terminal half-life of approximately 68 hours (range 35–96 h) after multiple doses, allowing once-daily dosing and a prolonged post-antibiotic effect.
The terminal elimination half-life of erythromycin base is approximately 1.5-2 hours in patients with normal renal function. In patients with end-stage renal disease, the half-life may be prolonged to 4-6 hours. The half-life is not significantly altered in hepatic impairment, but accumulation can occur with severe liver disease.
Primarily biliary/fecal (approx. 50% unchanged); renal excretion accounts for about 12% of the dose.
Erythromycin is primarily excreted in bile as active drug and metabolites, with approximately 12-15% of an administered dose excreted unchanged in urine. Fecal elimination accounts for about 30-60% of the dose, largely due to biliary excretion.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic